The Subjective Effects of Psychedelics Are Necessary for Their Enduring Therapeutic Effects
Top Cited Papers
- 10 December 2020
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Pharmacology & Translational Science
- Vol. 4 (2) , 568-572
Abstract
Classic psychedelics produce altered states of consciousness that individuals often interpret as meaningful experiences. Across a number of human studies, when the participant-rated intensity of the overall drug effects are statistically controlled for, certain subjective effects predict therapeutic and other desirable outcomes. Underlying neurobiological mechanisms are likely necessary but not sufficient to confer full and enduring beneficial effects. We propose that the subjective effects of psychedelics are necessary for their enduring beneficial effects and that these subjective effects account for the majority of their benefit.Keywords
Funding Information
- Steven and Alexandra Cohen Foundation
This publication has 28 references indexed in Scilit:
- Effects of Psilocybin-Assisted Therapy on Major Depressive DisorderJAMA Psychiatry, 2021
- Psychedelics, but Not Ketamine, Produce Persistent Antidepressant-like Effects in a Rodent Experimental System for the Study of DepressionACS Chemical Neuroscience, 2020
- Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network functionPharmacology & Therapeutics, 2019
- Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trialJournal of Psychopharmacology, 2016
- Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trialJournal of Psychopharmacology, 2016
- Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility studyThe Lancet Psychiatry, 2016
- PsychedelicsPharmacological Reviews, 2016
- Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept studyJournal of Psychopharmacology, 2015
- Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addictionJournal of Psychopharmacology, 2014
- Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist actionNeuroReport, 1998